When Dr. Clay Siegall founded his company, Seattle Genetics, in 1998, he has acquired over twenty years experience in cancer research. This experience has set the goals of Seattle Genetics to give Doctors better cancer treatment tools, and to help treat cancer patients with better therapies for everyday living.
These goals are personal for Clay as he watched his own father pass away from suffering with cancer for years. As a young man, this experience has had a profound impact on Clay, so he dedicated himself to finding a more advanced way of treating cancer.
Under Clay Siegall‘s leadership, he has raised 1.2 billion to date to fund cancer research and treatment. One cancer treatment that has been generated is ADCETRIS. This medicine is an ADC (antibody drug conjugate). ADC target only cancer cells, and will leave healthy cells intact. This is significant for cancer patients as it will decrease healing time and lessen side effects often seen in traditional cancer treatments.
ADCETRIS has currently been approved in over 64 countries as a viable treatment option and Seattle Genetics has entered into partnerships with other pharmaceutical companies sharing the ADC technology. Right now there are over 20 ADCs been produced thanks to this partnership.
Dr. Siegall entered the workforce years ago, first working for National Cancer Institute, National Institutes of Health as a researcher, and for Bristol-Myers Squibb Pharmaceutical Research Institute before building his own business.
Dr. Siegall is passionate about cancer treatment and the overall medical treatment of cancer patients. That is why Clay also serves on the boards of Alder BioPharmaceuticals and Ultragenyx Pharmaceutical. And on the Board of Directors for Washington Roundtable. Dr. Siegall has received his Bachelors of Science in Zoology from the University of Maryland, and his PhD in Genetics from George Washington University.